Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology

Augusto García-Agúndez, Elena Garcı́a-Martı́n, Carsten EickhoffFrontiers in Pharmacology 2022 · DOI · OpenAlex

Abstract

One of the potential applications of machine learning (ML) in pharmacogenomics is to improve dose prediction accuracy, thereby enhancing clinical outcomes and reducing adverse drug events (ADEs). In this context, Steiner et al. employed regression models to predict stable warfarin dosages in a diverse cohort of US Latinos and Latin Americans. Their findings suggest that incorporating ethnicity and warfarin indication—alongside the variables recommended by the International Warfarin Pharmacogenetics Consortium—yields a small but significant improvement in dose prediction. Additionally, the "Adversome" approach has emerged as a novel network-based method to detect ADEs and disease-related syndromes in rapidly changing, low-resource environments, such as the COVID-19 pandemic. Utilizing the FDA Spontaneous Adverse Events Reporting System (FAERS), this network effectively pinpoints ADEs for repurposed drugs. This Research Topic highlights the transformative role of ML in personalizing medicine and has been re-launched to invite further contributions.

Introduction

The fields of pharmacogenetics, pharmacogenomics, and pharmacoepidemiology are currently facing an unprecedented data deluge. Information critical to tailoring drug treatments—ranging from Electronic Health Records (EHRs) and millions of PubMed abstracts to massive databases like the FDA’s adverse event reports—is abundant but often "intractable." The primary challenge lies in the nature of this data: much of it is unstructured, consisting of free-text clinical notes or dense research papers, or is too complex for traditional statistical methods to navigate effectively.

Traditional approaches often struggle to capture the nuanced patterns required to predict individual patient responses to medication. This editorial introduces a collection of research that leverages Machine Learning (ML) to bridge this gap. By applying advanced algorithms to diverse datasets, researchers are improving dosage accuracy, predicting adverse drug events (ADEs), and automating the discovery of genomic associations, ultimately moving closer to the goal of truly personalized medicine.

Methodology and Data Sources

The research featured in this topic utilizes a variety of ML methodologies to extract insights from complex biological and clinical data:

  • Regression Modeling: Applied to refine dosage predictions, particularly for medications with narrow therapeutic windows like warfarin.
  • Support Vector Machines (SVM): Used to classify medication risk levels by analyzing historical adverse event data, particularly for predicting fetal teratogenicity.
  • Natural Language Processing (NLP) & Text-Mining: Leveraging tools like PubTator Central for entity recognition to automatically extract genome-chemical relationships from the vast corpus of PubMed literature.
  • Network Analysis (Adversome): A novel approach designed for high-speed or low-resource environments, such as a pandemic, to detect syndromes and comorbidities related to drug use.

These methods were trained and validated using a mix of clinical cohorts and large-scale public databases, including:

  • Diverse Patient Cohorts: Specifically, a cohort of US Latinos and Latin Americans was used to study warfarin dosing.
  • FDA Spontaneous Adverse Events Reporting System (FAERS): This served as the "ground truth" for training models to predict fetal teratogenicity and for identifying ADEs in drugs repurposed for COVID-19.
  • PubMed/PubTator Central: The primary source for automated pharmacogenomic association discovery through text-mining.

Key Insights and Results

Enhancing Representation in Algorithms

A significant finding from the work of Steiner et al. is that "one-size-fits-all" ML models may overlook critical factors for underrepresented populations. By adding ethnicity and specific clinical indications to the standard variables used for warfarin dosing, the researchers achieved a small but significant improvement in prediction accuracy for Latino populations. This underscores the necessity of including diverse demographic data in clinical algorithms to ensure equitable healthcare outcomes.

Predicting Risks for New Medications

ML demonstrates a unique capability to predict risks for new medications where clinical evidence is sparse. For instance, for novel antiseizure drugs, SVM-based models can utilize historical data from similar drug classes to predict risks like fetal teratogenicity before they become widespread clinical issues. In comparative studies, these ML approaches outperformed existing state-of-the-art methods in identifying developmental risks.

Automating Knowledge Discovery

The sheer volume of scientific literature makes manual review impossible for individual researchers. NLP and text-mining techniques can now "read" PubMed to identify potential genome-chemical pairs, effectively transforming unstructured scientific literature into a structured, searchable database for pharmacogenomic research. This automation significantly accelerates the pace of discovery.

Agility in Clinical Crises

The "Adversome" network approach proved particularly valuable during the COVID-19 pandemic. When drugs were being repurposed at an unprecedented rate, this ML-driven network was more adept than conventional epidemiological approaches at pinpointing adverse reactions in rapidly changing environments. This agility is crucial for public health responses during emerging crises.

Limitations and Future Directions

While the potential of AI and ML in clinical decision support is clear, several hurdles remain before widespread integration:

  • Clinical Integration: Moving from theoretical models to real-world clinical decision-making systems requires extensive validation and seamless integration into existing healthcare workflows.
  • Data Quality: Models relying on databases like FAERS must account for "noise," as these systems depend on spontaneous, often inconsistent, reporting.
  • Ongoing Research: The re-launch of this Research Topic signals a continued need for innovation. Future work should focus on refining these models, expanding their application to a broader range of drug classes, and ensuring they perform reliably across diverse global populations.

The integration of ML into pharmacogenetics and related fields represents a paradigm shift, offering the tools necessary to turn "intractable" data into actionable clinical insights.

Summary updated

Abstract

One of the potential applications of ML in pharmacogenomics is to improve dose prediction accuracy, improving outcomes and reducing adverse drug events (ADEs). In this context, Steiner et al.(https://www.frontiersin.org/articles/10.3389/fphar.2021.749786/full) employ regression to predict stable warfarin dosages in a diverse cohort that includes US Latinos and Latin Americans, concluding that the inclusion of ethnicity and warfarin indication, in addition to the International Warfarin Pharmacogenetics Consortium's recommended set of variables can result in a small but significant improvement in correct dose prediction. Adversome, a new approach to detect ADEs and other disease-and comorbidity-related syndromes in rapidly changing and low-resource environments such as the COVID epidemic. This network also uses FAERS as their data source to better pinpoint ADEs caused by drugs repurposed for COVID, better adapted than conventional approaches in the aforementioned context.We are happy to announce that this Research Topic has been re-launched and we look forward to new contributions in the coming months.
BibTeX
@inproceedings{garciaagundez2022editorial,
  author = {Augusto García-Agúndez and Elena Garcı́a-Martı́n and Carsten Eickhoff},
  title = {{Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.928527},
}
Figure